BIOASTER
Derry Mercer has extensive work experience in the field of antimicrobial research and development. From 1996 to 2004, Mercer served as a Principle Investigator at the Rowett Research Institute. In 2005, Mercer joined NovaBiotics Ltd as a Principal Scientist, where they focused on antimicrobial drug discovery and development. They worked on various aspects of drug discovery, including microbiology, molecular biology, toxicity, and drug design. Mercer held this position until 2023 while also taking on additional roles as Head of Antimicrobials and Responsable du Programme Antimicrobiens at BIOASTER. In 2020, Mercer became a Trustee at the Biochemical Society and an Honorary Policy Officer. Additionally, Mercer served as a Visiting Professor at Robert Gordon University starting in 2013.
Derry Mercer completed a Bachelor of Science (BSc) (Hons) degree in Microbiology, General from the University of Liverpool. This education took place from 1987 to 1991. Following this, Derry pursued a Doctor of Philosophy (Ph.D.) degree in Microbiology, General from the same university. This doctoral program lasted from 1991 to 1994.
BIOASTER
1 followers
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to : -Fight antimicrobials resistance. -Improve vaccines safety and efficacy. -Quickly diagnose infections at patient bedside. -take full advantage to human and animal microbiota. In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units. Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures. BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries. More information on www.bioaster.org